H.C. Wainwright lowered the firm’s price target on Aptose Biosciences (APTO) to $2 from $7 and keeps a Buy rating on the shares. The firm expects share count and warrant increases to provide funding to advance tuspetinib further in the clinic. It also pushed out projected launch years of tuspetinib starting with 2027 to 2029.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on APTO: